Abstract
In 2007, five Emerging Infections Program (EIP) sites were funded to determine the feasibility of establishing a population-based surveillance system for monitoring the effect of human papillomavirus (HPV) vaccine on pre-invasive cervical lesions. The project involved active population-based surveillance of cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma in situ as well as associated HPV types in women >18 years of age residing in defined catchment areas; collecting relevant clinical information and detailed HPV vaccination histories for women 18-39 years of age; and estimating the annual rate of cervical cancer screening among the catchment area population. The first few years of the project provided key information, including data on HPV type distribution, before expected effect of vaccine introduction. The project's success exemplifies the flexibility of EIP's network to expand core activities to include emerging surveillance needs beyond acute infectious diseases. Project results contribute key information regarding the impact of HPV vaccination in the United States.
Highlights
In 2007, five Emerging Infections Program (EIP) sites were funded to determine the feasibility of establishing a population-based surveillance system for monitoring the effect of human papillomavirus (HPV) vaccine on pre-invasive cervical lesions
In the United States, type-specific HPV infection and genital warts are being monitored in a variety of settings to evaluate the earliest evidence of vaccine effect, and HPVassociated cancers are monitored through the National Cancer Institute’s Surveillance, Epidemiology, and End Results program and the Centers for Disease Control and Prevention (CDC)–administered National Program of Cancer Registries, which cover the entire US population [8,9]
Preinvasive cervical intraepithelial neoplasia 2 and 3 and adenocarcinoma in situ, which are detected through routine screening, take less time to develop and were used as a surrogate for cervical cancer in vaccine trials
Summary
In 2007, five Emerging Infections Program (EIP) sites were funded to determine the feasibility of establishing a population-based surveillance system for monitoring the effect of human papillomavirus (HPV) vaccine on pre-invasive cervical lesions. In the United States, type-specific HPV infection and genital warts are being monitored in a variety of settings to evaluate the earliest evidence of vaccine effect, and HPVassociated cancers are monitored through the National Cancer Institute’s Surveillance, Epidemiology, and End Results program and the Centers for Disease Control and Prevention (CDC)–administered National Program of Cancer Registries, which cover the entire US population [8,9].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
